SCYX
NASD SCYNEXIS, Inc.$4.55 ↓ -0.11 (-2.29%) Trading Down from the previous close of $4.66
- YTD change
- -10.00%
- vs 20-day SMA
- -3.80%
- vs 200-day SMA
- -19.34%
Price ranges
Price & Performance
+3.87 (+490.10%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.0% away from all-time highs of $440.80
- SCYX is down 10% since the beginning of the year
- SCYX is down 26% over the past 12 months
- SCYX is down 13% over the past 1 month
- 5% of all SCYX investors are betting against SCYX
SCYX reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is +505.2%.
- Previous minute
- +$0.00
- Last hour
- +$0.04
- Last 5 days
- -6.31%
- vs 8-day SMA
- -0.14%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.